Patents by Inventor Kashi Javaherian
Kashi Javaherian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11845784Abstract: The present invention pertains to a method for producing a protein oligomer comprising at least two, and preferably three heterodimeric human NC-I-Fc proteins, the method comprising: a) culturing a host cell expressing (i) a fusion protein comprising, from N- to C-terminus, human NC-1 from collagen 18 fused to human IgGI Fc with “knob” mutations, or human IgGI Fc with “knob” mutations fused to human NC-1 from collagen 18, and (ii) human IgGI Fc with “hole” mutations, under conditions which allow the formation of a protein oligomer comprising at least two, and preferably three heterodimeric human NC-1-Fc proteins, and wherein the fusion protein of (i) and the human IgGI Fc with “hole” mutations of (ii) are expressed in a ratio of 2:1 or higher, and b) obtaining the protein oligomer comprising at least two, and preferably three heterodimeric human NC-1-Fc proteins.Type: GrantFiled: April 16, 2019Date of Patent: December 19, 2023Assignee: Heidelberg Biotech GmbHInventors: Kashi Javaherian, Jürgen Debus, Amir Abdollahi
-
Publication number: 20230382975Abstract: The present invention is concerned with a protein oligomer comprising (i) at least two NC-1 monomers of collagen 18 or (ii) at least two endostatin domains of collagen 18 or (iii) at least two N-terminal peptides of the collagen 18 endostatin domain, for use in treating, ameliorating or preventing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease.. The invention further relates to the mentioned protein oligomer for use for detecting and/or diagnosing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease.Type: ApplicationFiled: November 22, 2022Publication date: November 30, 2023Inventors: Amir Abdollahi, Kashi Javaherian, Jürgen Debus, Cheng Zhou
-
Publication number: 20230341406Abstract: The present invention is concerned with a protein oligomer comprising at least two NC-1 monomers of human collagen 18 or fragments of an NC-1 monomer of human collagen 18 for use in the treatment or prevention of an angiogenesis-related disease. The invention further pertains to a fusion protein comprising a NC-1 monomer of human collagen 18 and a Fc domain of an immunoglobulin. The invention also relates to a fusion protein comprising: a) an endostatin peptide or endostatin-derived peptide and b) the RGD motif and/or PHSRN motif of Fibronectin. The invention further relates to a kit comprising the protein oligomer or fusion proteins of the invention.Type: ApplicationFiled: October 14, 2022Publication date: October 26, 2023Applicant: Deutsches KrebsforschungszentrumInventors: Tong-Young LEE, Amir ABDOLLAHI, Kashi JAVAHERIAN
-
Patent number: 11548934Abstract: The present invention is concerned with a protein oligomer comprising (i) at least two NC-monomers of collagen 18 or (ii) at least two endostatin domains of collagen 18 or (iii) at least two N-terminal peptides of the collagen 18 endostatin domain, for use in treating, ameliorating or preventing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease. The invention further relates to the mentioned protein oligomer for use for detecting and/or diagnosing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease.Type: GrantFiled: December 5, 2016Date of Patent: January 10, 2023Assignee: Deutsches KrebsforschungszentrumInventors: Amir Abdollahi, Kashi Javaherian, Jürgen Debus, Cheng Zhou
-
Publication number: 20210363225Abstract: The present invention pertains to a method for producing a protein oligomer comprising at least two, and preferably three heterodimeric human NC-I-Fc proteins, the method comprising: a) culturing a host cell expressing (i) a fusion protein comprising, from N- to C-terminus, human NC-1 from collagen 18 fused to human IgGI Fc with “knob” mutations, or human IgGI Fc with “knob” mutations fused to human NC-1 from collagen 18, and (ii) human IgGI Fc with “hole” mutations, under conditions which allow the formation of a protein oligomer comprising at least two, and preferably three heterodimeric human NC-1-Fc proteins, and wherein the fusion protein of (i) and the human IgGI Fc with “hole” mutations of (ii) are expressed in a ratio of 2:1 or higher, and b) obtaining the protein oligomer comprising at least two, and preferably three heterodimeric human NC-1-Fc proteins.Type: ApplicationFiled: April 16, 2019Publication date: November 25, 2021Inventors: Kashi Javaherian, Jürgen Debus, Amir Abdollahi
-
Publication number: 20200270332Abstract: The present invention is concerned with a protein oligomer comprising (i) at least two NC-monomers of collagen 18 or (ii) at least two endostatin domains of collagen 18 or (iii) at least two N-terminal peptides of the collagen 18 endostatin domain, for use in treating, ameliorating or preventing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease. The invention further relates to the mentioned protein oligomer for use for detecting and/or diagnosing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease.Type: ApplicationFiled: December 5, 2016Publication date: August 27, 2020Inventors: Amir Abdollahi, Kashi Javaherian, Jürgen Debus, Cheng Zhou
-
Publication number: 20140302026Abstract: The present invention is concerned with a protein oligomer comprising at least two NC-1 monomers of human collagen 18 or fragments of an NC-1 monomer of human collagen 18 for use in the treatment or prevention of an angiogenesis-related disease. The invention further pertains to a fusion protein comprising a NC-1 monomer of human collagen 18 and a Fc domain of an immunoglobulin. The invention also relates to a fusion protein comprising: a) an endostatin peptide or endostatin-derived peptide and b) the RGD motif and/or PHSRN motif of Fibronectin. The invention further relates to a kit comprising the protein oligomer or fusion proteins of the invention.Type: ApplicationFiled: August 23, 2012Publication date: October 9, 2014Applicant: Deutsches KrebsforschungszentrumInventors: Tong-Young Lee, Amir Abdollahi, Kashi Javaherian
-
Patent number: 7645735Abstract: Provided herein are peptides from the N-terminal of endostatin proteins, including the first histidine of the protein, nucleic acids encoding the peptides, pharmaceutical compositions comprising the nucleic acids and proteins and methods for using the pharmaceutical compositions to treat or prevent endometriosis in a subject.Type: GrantFiled: February 28, 2006Date of Patent: January 12, 2010Assignee: Children's Medical Center CorporationInventors: Judah Folkman, Kashi Javaherian, Christian Becker, Robert D'Amato
-
Publication number: 20090280190Abstract: Provided herein are anti-angiogenic comprising the N-terminal end of endostatin, nucleic acids encoding the same, pharmaceutical preparations comprising an effective amount of the peptide and nucleic acids and use of the pharmaceuticals in treating or preventing diseases or conditions associated with undesirable angiogenesis.Type: ApplicationFiled: March 6, 2009Publication date: November 12, 2009Inventors: Judah Folkman, Kashi Javaherian, Robert Tjin Tham Sjin
-
Patent number: 7524811Abstract: Provided herein are anti-angiogenic comprising the N-terminal end of endostatin, nucleic acids encoding the same, pharmaceutical preparations comprising an effective amount of the peptide and nucleic acids and use of the pharmaceuticals in treating or preventing diseases or conditions associated with undesirable angiogenesis.Type: GrantFiled: February 28, 2006Date of Patent: April 28, 2009Assignee: Children's Medical Center CorporationInventors: Judah Folkman, Kashi Javaherian, Robert Tjin Tham Sjin
-
Publication number: 20060258583Abstract: Provided herein are peptides and nucleic acids encoding the peptides, pharmaceutical compositions comprising the nucleic acids and proteins and methods for using the pharmaceuticals to treat or prevent endometriosis in a subject.Type: ApplicationFiled: February 28, 2006Publication date: November 16, 2006Applicant: Children's Medical Center CorporationInventors: Judah Folkman, Kashi Javaherian, Christian Becker, Robert D'Amato
-
Publication number: 20060251699Abstract: Provided herein are anti-angiogenic comprising the N-terminal end of endostatin, nucleic acids encoding the same, pharmaceutical preparations comprising an effective amount of the peptide and nucleic acids and use of the pharmaceuticals in treating or preventing diseases or conditions associated with undesirable angiogenesis.Type: ApplicationFiled: February 28, 2006Publication date: November 9, 2006Applicant: Children's Medical Center CorporationInventors: Judah Folkman, Kashi Javaherian, Robert Sjin
-
Publication number: 20050196402Abstract: CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. The nucleic acids of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins in a variety of hosts, particularly eukaryotic cells. The CTLA4-immunoglobulin fusion proteins described herein can be administered to a subject to inhibit an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) on an antigen presenting cell and a receptor for the CTLA4 ligand (e.g.Type: ApplicationFiled: November 8, 2004Publication date: September 8, 2005Applicant: REPLIGEN CORPORATIONInventors: Gary Gray, Jerry Carson, Kashi Javaherian, Paul Rennert, Sandra Silver
-
Publication number: 20040151725Abstract: CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. The nucleic acids of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins in a variety of hosts, particularly eukaryotic cells. The CTLA4-immunoglobulin fusion proteins described herein can be administered to a subject to inhibit an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) on an antigen presenting cell and a receptor for the CTLA4 ligand (e.g.Type: ApplicationFiled: March 2, 2004Publication date: August 5, 2004Inventors: Gary S. Gray, Jerry Carson, Kashi Javaherian, Cindy L. Jellis, Paul D. Rennert, Sandra Silver
-
Patent number: 6750334Abstract: CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. The nucleic acids of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins in a variety of hosts, particularly eukaryotic cells. The CTLA4-immunoglobulin fusion proteins described herein can be administered to a subject to inhibit an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) on an antigen presenting cell and a receptor for the CTLA4 ligand (e.g.Type: GrantFiled: February 2, 1996Date of Patent: June 15, 2004Assignee: Repligen CorporationInventors: Gary S. Gray, Jerry Carson, Kashi Javaherian, Cindy L. Jellis, Paul D. Rennert, Sandra Silver
-
Patent number: 6444792Abstract: CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. The nucleic acids of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins in a variety of hosts, particularly eukaryotic cells. The CTLA4-immunoglobulin fusion proteins described herein can be administered to a subject to inhibit an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) on an antigen presenting cell and a receptor for the CTLA4 ligand (e.g.Type: GrantFiled: January 8, 1999Date of Patent: September 3, 2002Assignee: Repligen CorporationInventors: Gary S. Gray, Jerry Carson, Kashi Javaherian, Paul D. Rennert, Sandra Silver
-
Publication number: 20020114814Abstract: CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. The nucleic acids of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins in a variety of hosts, particularly eukaryotic cells. The CTLA4-immunoglobulin fusion proteins described herein can be administered to a subject to inhibit an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) on an antigen presenting cell and a receptor for the CTLA4 ligand (e.g.Type: ApplicationFiled: December 20, 2001Publication date: August 22, 2002Inventors: Gary S. Gray, Jerry Carson, Kashi Javaherian, Paul D. Rennert, Sandra Silver